Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 6
Submit an article Journal homepage
568
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma

Ravi K. Goyala Department of Health Economics, RTI Health Solutions, Research Triangle Park, NC, USAORCID Iconhttps://orcid.org/0000-0003-1632-036XView further author information
ORCID Icon,
Preetesh Jainb Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Saurabh P. Nagara Department of Health Economics, RTI Health Solutions, Research Triangle Park, NC, USAView further author information
,
Hannah Lec US HEOR Oncology, AstraZeneca, Gaithersburg, MD, USAView further author information
,
Shaum M. Kabadid Epidemiology and Real-World Evidence in Oncology, AstraZeneca, Gaithersburg, MD, USAView further author information
,
Keith Davisa Department of Health Economics, RTI Health Solutions, Research Triangle Park, NC, USAView further author information
,
James A. Kayee Department of Epidemiology, RTI Health Solutions, Waltham, MA, USAView further author information
,
Xianglin L. Duf The University of Texas Health Science Center at Houston, Houston, TX, USACorrespondence[email protected]
View further author information
&
Michael Wangb Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9748-5486View further author information
ORCID Icon show all
Pages 1325-1334 | Received 04 Jan 2021, Accepted 06 Apr 2021, Published online: 08 May 2021

References

  • Fu S, Wang M, Lairson DR, et al. Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: a comparative study between Texas and National SEER areas. Oncotarget. 2017;8(68):112516–112529.
  • National Comprehensive Cancer Network (NCCN) [Internet]. Clinical practice guidelines in oncology: B-cell lymphomas. Version 1. 2017. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2020. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx
  • Goyal RK, Nagar SP, Kabadi SM, et al. Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States. Leuk Lymphoma. 2019;60(4):955–963.
  • Kozma CM, Slaton T, Ellis R, et al. Healthcare resource utilization (HRU) in treated mantle cell lymphoma (MCL) patients. Cancer Res. 2014;74(19 Suppl):4139.
  • Griffiths R, Mikhael J, Gleeson M, et al. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood. 2011;118(18):4808–4816.
  • Charlson ME, Charlson RE, Peterson JC, et al. The Charlson Comorbidity Index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234–1240.
  • Chyou JY, Hunter TD, Mollenkopf SA, et al. Individual and combined risk factors for incident atrial fibrillation and incident stroke: an analysis of 3 million at-risk US patients. J Am Heart Assoc. 2015;4(7):e001723.
  • Danese MD, Reyes CM, Gleeson ML, et al. Estimating the population benefits and costs of rituximab therapy in the United States from 1998 to 2013 using real-world data. Med Care. 2016;54(4):343–349.
  • Hurvitz S, Guerin A, Brammer M, et al. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting. Oncologist. 2014;19(9):901–908.
  • Griffiths RI, Gleeson ML, Mikhael J, et al. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. Cancer. 2012;118(24):6079–6088.
  • Lipsky A, Martin P. Bendamustine–rituximab in mantle cell lymphoma. Lancet Haematol. 2017;4(1):e2–e3.
  • Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 2019;94(6):710–725.
  • Ye H, Desai A, Zeng D, et al. Frontline treatment for older patients with mantle cell lymphoma. Oncologist. 2018;23(11):1337–1348.
  • Olszewski AJ, Butera JN, Reagan JL, et al. Outcomes of bendamustine‐ or cyclophosphamide‐based first‐line chemotherapy in older patients with indolent B‐cell lymphoma. Am J Hematol. 2019;95(4):354–361.
  • Kabadi SM, Near A, Wada K, et al. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States. Cancer Med. 2019;8(17):7174–7185.
  • Cheah CY, Chihara D, Romaguera JE, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175–1179.
  • Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17(1):57–66.
  • Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–745.
  • Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine–rituximab or RCHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–2952.
  • Flinn IW, van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019;37(12):984–991.
  • Imbruvica (ibrutinib). Prescribing information; 2020; [cited 2020 Mar 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205552s030,210563s006lbl.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.